Navigation Links
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Date:7/1/2008

that typically affects children and young adults.

In January 2008, the Company announced that, following presentation of data at an oral explanation hearing before the CHMP, the CHMP determined in a non-binding opinion that L-MTP-PE suggested a possible clinical benefit in terms of survival and granted the Company a clock-stop, or time extension. The clock-stop allowed IDM Pharma additional time to respond to remaining questions regarding the MAA. At that time, the CHMP requested clarification of the existing data in order to gain assurance about the quality of the data before drawing any final conclusions from the data presented. In addition, the Company was required to address a number of remaining questions relating to CMC.

In April 2008, the European regulatory authorities conducted an inspection of the COG to assess the quality of the overall survival data from the 2006 confirmatory database included in the Company's applications for regulatory approval, and to review Good Clinical Practice (GCP) compliance of the COG in terms of patient randomization and stratification, overall survival data collection, and study monitoring. The Company supported the COG in this effort.

Following the GCP inspection in April and the June CHMP meeting, the CHMP requested that the Company provide additional data analyses from the Phase 3 L-MTP-PE trial (INT-0133), in addition to responding to the remaining CMC questions. The Company believes that the additional data analyses requested will further confirm the overall survival benefit of L-MTP-PE seen in the data analyses previously provided.

L-MTP-PE was granted orphan drug status in Europe in 2004. The MAA for L-MTP-PE was submitted to the EMEA and accepted for regulatory review in November 2006.

L-MTP-PE U.S. Regulatory Status

As previously announced, in the United States the Company continues to work with the COG as well as external experts and advisors to gather patient follow-up dat
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Isis Pharmaceuticals Conference Call Notice
2. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
3. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
4. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
5. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
6. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
7. Pharmasset Receives Notice of Allowance
8. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
9. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... On Thursday, July 10, 2014, the ... Industrial Average finished the day 0.42% lower at 16,915.07, and ... were broad based as eight out of ten sectors ended ... Index ended the day at 711.88, down 0.02%, while the ... has initiated coverage on the following equities: Covidien PLC (NYSE: ...
(Date:7/11/2014)... DIEGO , July 11, 2014 Neurelis, ... Corp. ("Biotie") to end the option held by Biotie ... commence further development of NRL-1 (intranasal diazepam) for pediatric ... Over the past year, Biotie has advanced ... in preparation for the pivotal clinical work required for ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... , , , Funding and ... NEW YORK, Dec. 14 The Microbicides Development Programme announced ... conducted among almost 9,400 women in four African countries, found ... of HIV infection. , Reacting to today,s announcement, AVAC executive ...
... InterMune, Inc. (Nasdaq: ITMN ) today announced that Steve ... the 2009 DB-Biotech Boston Confab on December 15, 2009 at ... audio webcast of the presentation, investors and other interested parties ... corporate website at www.intermune.com. The company recommends logging on ...
Cached Medicine Technology:AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial 2AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial 3
(Date:7/13/2014)... is a professional supplier of funeral products. According to the ... in the global market. Recently, the company has announced its ... special offer for all the newly released items. , ... are made with superb materials. As is commonly noted, a ... to the departed saint. MillionaireCasket.com is always here to help. ...
(Date:7/13/2014)... to get the best treatment and variations in the ... survival for blood cancer patients still varies widely between ... of survival in European adults to date, published in ... is that 5-year survival for most cancers of the ... likely reflecting the approval of new targeted drugs in ...
(Date:7/13/2014)... Carolinas Healthcare System celebrated today the ... HealthCare System - Anson located in Anson County. The ... Hospital in Wadesboro. , Located on U.S. Highway 74, ... previous facility. Situated on a 10-acre site, the new ... room drop-off, helipad, healing garden, and 15 beds. With ...
(Date:7/13/2014)... identifies a novel genetic and molecular pathway in ... up potential new therapeutic strategies for an enigmatic ... a chronic inflammatory disorder of the esophagus. The ... foods and an over-accumulation in the esophagus of ... body,s immune system). EoE can cause a variety ...
(Date:7/13/2014)... 2014 Chromatography system is a ... various types of biological samples such as air ... mixture into two phase, namely mobile phase and ... run over the stationary phase, followed by the ... provide the separation of mixture. Chromatography system plays ...
Breaking Medicine News(10 mins):Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3
... fibronectin can predict whether a pregnant woman is at ... risk for pre-term births are women with previous pre-term ... suffer from diabetes and/or hypertension. The current approach for ... is the use of a clinical scoring system, ...
... technology born of genetic ,engineering, and known as naked ... such as multiple ,sclerosis and rheumatoid arthritis. , ... In multiple sclerosis (MS) and ,rheumatoid arthritis (RA), the ... myelin sheath of nerves falls ,victim, while in RA, ...
... requiring heart bypass ,speeds recovery in children undergoing ... clinical trial published in The Lancet., , ... underwent long and difficult surgeries. Following trauma or ... concentrations plummet. Many experts thought this was an ...
... derivatives from garlic may potentially play a role in ... review published in a recent issue of Nutrition in ... effect of garlic on risk factors for heart disease. ... LDL ("bad") ,cholesterol and blood pressure. It may also ...
... painkillers to ease the agony of terminally ill patients ... the practice, comparing it to euthanasia, but doctors at ... doses of drugs such as morphine live just as ... research published in The Lancet medical journal, they compared ...
... Antibiotcs seem to treat or prevent the symptoms of autism ... is affected by autism. Currently there are no treatments for ... found that a subset of patients with autism who experience ... by antibiotic vancomycin. ,Interestingly the study was done ...
Cached Medicine News:
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for contralateral access to the iliac artery for interventional procedures after initial wire guide positioning has been established.,NOTE: Use of a heavy-duty wire guide is recommended....
Medicine Products: